As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention
The funding decisions made at the Bio International Convention will create bioscience centers of innovation in biomaterials and plant biology, expand cancer drug development efforts, and create a strong bioenergy research partnership between the
Centers of innovation
The Kansas Innovation Center for Advanced Plant Design will receive
The center is a public and private collaboration of Kansas Wheat,
The KBA also will invest
Partnering to form this center are
This brings the number of approved centers of innovation to four after the March approval of the Kansas Bioscience Innovation Center in Drug Delivery and Kansas Bioenergy and Biorefining Center of Innovation.
Cancer drug development
Adding to the investment of more than
Lenexa-based CyDex Pharmaceuticals will receive $195,000to commercialize re-formulated drugs that address limitations of existing therapies. A focus will be improving a cancer drug for patients with multiple myeloma (cancer of the Plasma B cells formed in the bone marrow).
- CritiTech and SCF Technologies of
Lawrencewere awarded $50,000to further develop a novel approach to converting drugs into dry, sterile powder form. The process is expected to significantly reduce costs in drug manufacturing, while easing the process of administering drugs for both physicians and patients. The investment is a partial match to a $100,000grant from the National Cancer Institute.
Manhattan-based NanoScale will use $50,000in KBA matching funds to expedite the testing of nanoparticles for diagnostic and therapeutic uses in fighting cancer. These “stealth” particles are expected to allow earlier disease detection and to improve the ability of drugs to hit their intended targets with fewer side effects. The company received a $150,000Small Business Innovation Research award from the National Institutes of Health.
$500,000Collaborative Cancer Research Initiative (CCRI) investment will go to the University of KansasCancer Center and Scripps Research Institute. The research is intended to reduce the unwanted toxicity often associated with chemotherapy and improve the treatment of breast and prostate cancers.
- A second
$500,000CCRI investment was approved to initiate Phase I clinical trials in the Wichitaarea through a partnership of the University of KansasCancer Center, Cancer Center of Kansas, Midwest Cancer Alliance and Via Christi Regional Medical Center. Phase I trials will complement the successful Phase II and III programs in Wichitaand strengthen rural and regional treatment options.
$600,000project budget was committed for the KBA to support the University of KansasCancer Center’s efforts to bring cutting-edge cancer treatments closer to home for millions of Kansans through National Cancer Institute designation.
Bioenergy research partnership
The KBA will provide
Approved investments are subject to final agreements between the KBA and investees.
About the KBA
The Kansas Bioscience Authority is a
SOURCE Kansas Bioscience Authority